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ABSTRACT
Performance Study of Graph Convolutional Networks for Medical Prediction-Based
Networks
Ben D’Antonio
Department of Computer Science and Engineering
Texas A&M University
Research Advisor: Dr. Anxiao Jiang
Department of Computer Science and Engineering
Texas A&M University
Predicting the effects of Polypharmacy is a difficult task, and a great amount of money
is spent annually remedying the effects of negative drug interactions arising from Polyphar-
macy. However, Machine Learning can be used to give more accurate predictions than tra-
ditional means. In this thesis, we survey current methods of applying Machine Learning
to Polypharmacy. We rigorously define a theoretical Polypharmacy problem and design a
Graph Convolutional Network that can learn to strongly model our problem. We discuss
its performance and offer future steps for generalizing the model to gain a better under-
standing of the field of Polypharmacy and the potential of Machine Learning to improve
it.
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NOMENCLATURE
AI Artificial Intelligence
DL Deep Learning
DNN Deep Neural Network
GCN Graph Convolutional Network
ML Machine Learning
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1. INTRODUCTION
Polypharmacy is the simultaneous use of multiple drugs to treat a single disease or
condition. Typically, the concurrent use of five or more drugs is considered Polypharmacy
[1]. The process of developing a single drug approved for human-use is arduous because
of the complex interactions any drug will have with the human body. The cost of taking a
drug from concept to market is estimated at $1.3 billion with an approval rate of around 1
out of 1000 [2]. When multiple drugs are used simultaneously to treat a disease, there is
a significant chance that a side-effect will arise from the drugs’ interactions, and the result
can greatly harm a person’s health. Each year, the U.S. alone spends an estimated $30
billion to $180 billion addressing issues caused by Polypharmacy [3]. These side-effects
are often harder to identify than side-effects arising from a single drug [4]. This problem
is further exacerbated by resource limitations, as rigorous testing of a drug’s interaction
with all marketed drugs is infeasible. Therefore, there is much to be done to improve
Polypharmacy practices.
One method to progress Polypharmacy’s state of the art is through the application of
Machine Learning (ML). ML is the process of having Artificial Intelligence (AI) learn to
perform a task without being provided explicit instructions. Instead, ML processes use
large bodies of data to identify patterns and make inferences based on them. For example,
given New York’s weather data over the past twenty years, a ML process could learn to
predict what New York’s weather will be tomorrow. Because the ML process is provided
no explicit instructions, however, it would have to identify the best metrics to predict the
weather, such as the weather the day before, on its own. In the beginning, like a child, the
ML process would do no better than naively guessing. To become more intelligent, the
ML process must practice like a human would. That is, the ML process needs to make
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a prediction, see if it was right or wrong, learn from it, and give a better prediction next
time. However, predicting the weather once a day is not the fastest way to learn. Instead
of telling the ML process to predict New York’s weather for tomorrow and then waiting a
day to see if its prediction was correct, the ML process can pick a date in the past, hide the
actual answer from itself, and then try to predict that date’s weather based on the weather
data before it. After practicing enough, through trial and error, it would learn to make
its prediction based on good metrics like the weather that day in past years, the weather
leading up to that day, and historical trends in New York’s weather. Through this cycle
of training, testing, and learning from feedback over a large body of accurate data, a ML
process can quickly develop expertise over a specific problem and make predictions like a
human would.
Because there exist large bodies of historical Polypharmacy data–and each drug’s prop-
erties are typically well understood–Polypharmacy stands to benefit greatly from ML.
Namely, using historical data about drugs; their interaction with specific diseases, dis-
orders, and proteins in human bodies; and any interactions with other drugs; ML can be
trained to predict the complex interactions that occur in Polypharmacy. Some of the tasks
ML can assist Polypharmacy in are the following:
• Identifying problematic interactions between drugs.
• Reinforcing previous findings in Polypharmacy.
• Providing a quick-access method of determining the risks of a set of drugs.
• Finding new, beneficial drug interactions in Polypharmacy.
The results of these benefits are the following:
• Reducing associated costs of Polypharmacy, including mortality rate and economic
resources.
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• Increasing our knowledge and understanding over the field of Polypharmacy.
• Centralizing and organizing Polypharmacy’s massive body of knowledge.
Thus, the motivation of this research is to assist in improving Polypharmacy with ML.
In this thesis, we survey current methods of using ML to improve Polypharmacy, propose a
theoretical model for a Polypharmacy data set, and create a Graph Convolutional Network
(GCN) model to train on the data set. The data is generated from a low-dimensional
(latent) space but is observable only in a high-dimensional (observation) space. This means
that the data is actually dependent on a small number of factors but is artificially stretched
to seem dependent on many factors. The GCN sees only the observation space of the
data and learns to make accurate predictions on the data set. The data set, while simple,
is nontrivial. We detail and discuss the knowledge gained from simulating a theoretical,
simple but nontrivial Polypharmacy data set on a GCN.
1.1 Current Methods of ML for Polypharmacy
The predominant subarea of ML being applied to Polypharmacy is Deep Learning
(DL). DL is a subset of ML inspired by how humans think and learn. DL models are
generally based on the structure and function of the brain itself. DL is applied to image
classification, outcome prediction, Natural Language Processing (NLP), and many other
actions that humans perform on a day-to-day basis. Deep Neural Networks (DNNs) is a
subarea of DL that epitomizes the concept of mimicking the human brain as a ML network.
DNNs are currently a popular ML model used in the field of Polypharmacy. As we will
see, DNNs have properties that are very useful for Polypharmacy.
In the human brain there are many interconnected cells called neurons. The relation-
ship between these neurons can be thought of as a very complex directed graph where each
node is a neuron. A neuron N receives impulses from neurons that have a directed edge
to N ; and, depending on the strength of the impulses, N may activate and send impulses
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to the neurons it has directed edges to, which may then activate other neurons, causing a
cascade effect. The graph of neurons has many source and sink neurons too. For example,
if an object collides with a person’s leg just below the knee, it will cause a physical sen-
sation that triggers a source neuron to send impulses to its connected neurons. Eventually,
the impulses will cascade far enough that the impulses reach the neurons responsible for
controlling the thigh muscle. The impulses will cause the leg muscle to contract, causing
the person’s knee to automatically kick out. This is how human reflexes work. Depend-
ing on how the graph of neurons, the neural network, is set up, certain stimulations can
deterministically cause certain reactions, such as reflexes.
Figure 1.1: A neuron receives electrical signals from other neurons. The neuron will send
a signal to its outgoing neurons depending on the strength of each impulse and how the
neuron values each incoming signal.
This neural network model also has the capability to learn from trial and error. To
do so, a neuron can value the impulses of its incoming connections independently; one
incoming neuron’s impulse may be valued as half as significant as another neuron. As an
action is performed repeatedly, based on feedback, a neuron may respond less and less to
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a certain neuron’s impulse but more so to another neuron’s. For example, when a person
attempts a task and does it right, the person feels happy. This feeling of happiness can be
feedback to the neural network; thus, the neurons involved with the task will start to value
the incoming impulses that resulted in positive feedback more. When the person does the
task wrong, the inverse will occur. Eventually, the neurons will determine which incoming
impulses generate the best result. This is how muscle memory is developed. There is
certainly much more to the field of Neuroscience, but this is sufficient for explaining the
fundamentals of DNNs.
Because of a neural network’s abilities to deterministically compute outputs based on
certain inputs and to learn from trial and error, it is unsurprisingly a powerful computa-
tional model which enables human intelligence. Fortunately, it is also a computational
model that can be approximately captured by computers.
1.2 Deep Neural Networks
As mentioned, a Neural Network can be modeled in Computer Science as a directed
graph consisting of thousands, millions, or more densely connected nodes, where each is
a neuron. These nodes are organized into layers with a unidirectional data flow. There
can be source and sink nodes throughout the network; however, generally, there is a single
input layer at the start of the network and a single output layer at the end. The layers in
between are called hidden layers, and they perform the computations. When an input is
received, depending on the intensity, the corresponding source node will activate with an
intensity measured in the form of a number, typically ranging from 0 to 1. The source
node then sends this number to each of its outgoing connections. For a non-source node
N , each of N ’s incoming connections are assigned a “weight"; some incoming connec-
tions are significantly more important than others and, thus, have a higher weight. The
node takes the number sent through the incoming connection–the “strength” of the incom-
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ing connection’s activation–and multiplies it by the weight assigned to that connection. If
there are multiple activated incoming connections, each of their values are weighted and
then summed. The node will then scale this number to the range 0 to 1, where 1 means the
activation is as strong as possible, and send this number to each of its outgoing connec-
tions. This propagates throughout the network and eventually arrives at sink nodes, where
output is generated. For a Neural Network, there can be many inputs. Returning to the
previous example for ML, one input to the Neural Network may be whether it rained the
day before; another input may be the average temperature for the previous week; and so
on. The outputs may be whether it will rain today and what the average temperature will
be.
Figure 1.2: Structure of a DNN.
A Neural Network is governed by weights, represented as numbers, which are de-
termined based on feedback. However, in the beginning, a Neural Network has had no
feedback and, thus, knows nothing. Unlike human brains, which have had millions of
years of feedback and start off with a well-tuned network, a Neural Network is created at
a moment’s notice and must learn to solve a complex problem in a short time span. To
address this, all nodes in the Neural Network initially receive random connection weights.
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Therefore, the network will do no better than randomly guess at the start. However, this
initialization scheme allows the network to quickly identify how helpful each node is early
on from its feedback. For example, if a node has some incoming connection weight initial-
ized as .999 but consistently gets the answer wrong, it may lower this weight and increase
the weight of its other incoming connections. Eventually, the network will instead begin
to consistently give correct outputs and proceed to reinforce what it has learned so far.
A DNN is simply a Neural Network with multiple hidden layers. More layers in a
DNN allow for the potential to model more complex problems; however, too many layers
can cause a network to become slow to learn because it has too factors to consider when
tuning itself. Such a trade off is a common balancing act in ML. For example, this problem
also affects the choice of the number of nodes in each hidden layer.
ML learning is divided into two alternating phases: training and testing. Both phases
provide a set of inputs to the DNN and evaluate the network’s performance. During train-
ing, the network tunes its values based on feedback from its prediction attempts; this is
where learning takes place. Unlike training, testing does not provide feedback to the net-
work. Instead, testing is used to simply evaluate the network’s performance. To evaluate a
network’s performance properly, it is important that the testing is unbiased. To accomplish
unbiased testing, the training and testing data sets are kept mutually exclusive. Thus, the
network will never see testing data during its training phase. The network will, therefore,
never receive feedback from any data in the testing set. Because of this, the testing results
are unbiased and serve as a good indication of the network’s actual grasp of the problem
it is solving. This presents another balancing act, however: because a network only re-
ceives feedback from its training phase, it may simply learn to give the correct answer for
input that is similar to its training data. Thus, when it finds unfamiliar data for the same
problem, it will predict incorrectly. This is called overfitting. Overfitting is indicated by a
high training accuracy but a low testing accuracy when making predictions. On the other
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hand, the network may be learning the general problem but is not doing particularly well
overall. This is called underfitting. Underfitting is indicated by both a low training and
low testing accuracy when making predictions. It is important to note that having a low
training accuracy and a high testing accuracy is very unlikely to occur because the network
exclusively fits itself on the training data. There are many parameters of DNNs that can
cause overfitting and underfitting; to name a few: the number of hidden layers, the number
of nodes in each hidden layer, the activation functions of each node, and the rate at which
random dropout of learned information occurs (to combat overfitting).
A GCN is a specific type of DNN. What has been covered thus far is enough to intro-
duce GCNs.
Figure 1.3: The relationship between the discussed forms of AI, from most general to most
specific.
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2. RELATEDWORKS
As first proposed by T. Kipf and M. Welling, a Graph Convolutional Network (GCN)
notably is a DNN that learns problems that can be modeled by graphs [5]. Many problems
that Computer Science is concerned with can be modeled by graphs, including social net-
works, the World Wide Web, and, of particular interest to our research, protein-interactions
in Polypharmacy [6][7][8]. For example, in a social network, each person can be repre-
sented as a node in a graph. If two people are mutual friends, an undirected edge exists
between them. Given an incomplete graph of a social network, a GCN can learn to predict
whether two people will be friends with each other and, thus, complete the graph. It may
learn to do so by observing trends in the graph. For example, if a person A has many
mutual friends with a person B, person A and person B are statistically likely to also be
friends. Additionally, a GCN can be supported by external information about each node,
called features. For example, in a social network, if everyone in the network takes a per-
sonality test, then a GCN may observe that people with very similar personalities tend to
more often be mutual friends. Combining the observable edges between nodes with fea-
ture information about each node, a GCN can learn to effectively predict things in a graph
like missing edges. Because Polypharmacy datasets are typically large, complex graphs,
GCNs are an excellent candidate for modeling these problems.
Recently, a lot of research has been done on the prospect of applying ML to Polyphar-
macy; this research has focused on laying the groundwork for applying ML techniques
like GCNs to Polypharmacy [9] [10] [11]. Overall, GCNs have sparked great interest as a
research topic, which focuses on improving GCNs’ scability and power and creating new
ML models based off GCNs [12] [13] [14]. Some of this research, such as creating an
attention-based GCN, may be applicable to this research in the future.
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2.1 Graph Convolutional Networks
A GCN takes as input a data representation of a graph (commonly an adjacency matrix)
and a feature matrix. A “feature” is a property of each node in the graph and is represented
as a number. For example, a feature in a group of people forming a social network may be
a measure of how patient each person is. The feature matrix is 2-dimensional. Each row
in the feature matrix is a feature vector corresponding to one node in the graph, a measure
of each node’s features. Each column in the feature matrix corresponds to a certain feature
which we believe is useful to our network for understanding the nodes and graph. Thus,
given a row and column, the location in the feature matrix is a feature value that represents
a specific node’s relationship with a specific property we believe useful to the network in
the form of a number. For example, in the Myers-Briggs Type Indicator test, there are four
personality traits (features) studied:
• Extraversion vs. Introversion
• Sensing vs. Intuition
• Thinking vs. Feeling
• Judging vs. Perceiving
We can represent each of these four features on a dense scale of 0 to 1, where a 0 means
that the person strongly exhibits the left trait, a 1 means the person strongly exhibits the
right trait, and a .5 means the person exhibits both traits to a moderate degree. If we
suppose we have a social network consisting of four people, then, after the personality
test, each of the four people will have four feature values, comprising four feature vectors
in the feature matrix:
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
1 0 .5 .75
.6 .9 .72 .54
0 .63 .5 0
.8 .6 .1 1

The first row is person A’s feature vector. It indicates that person A is strongly Intro-
verted, strongly Sensing, moderately Feeling and Thinking, and fairly Perceiving.
Then, let us suppose that following is the adjacency matrix describing these four peo-
ple’s social network:

1 0 1 0
0 1 1 0
0 1 1 0
0 1 0 1

Now we have established the inputs which the GCN uses to learn. The GCN learns
from these inputs through a process called convolving, which means entwining together.
The network entwines/combines/convolves feature information about each node together
with the provided graph in an attempt to understand why certain edges exist. We will
describe how a GCN uses convolving to learn.
A GCN, as with any DNN, consists of a number of hidden layers surrounded by an
input and output layer. A GCN’s string of hidden layers begins with a series of graph-
convolutional layers. Each graph-convolutional layer takes as input the adjacency matrix
representation of the graph, A, and a feature matrix, H , and outputs another feature matrix
with an arbitrary number of features. If the input feature matrix is (N × F ), the output
feature matrix is (N × F ′), where F ′ is an arbitrary number (typically smaller than F ).
The output feature matrix is the convolved information of A and H . This means that the
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output feature matrix contains the information of the input feature matrix combined in
some way with the information contained in the adjacency matrix. There are many ways
to “combine” the two matrices; one such method will be discussed briefly. Because we can
arbitrarily choose the number of output features of a graph-convolutional layer, we can set
up a series of graph-convolutional layers that take A and Hi−1 as input and output Hi:
Hi = f(A,Hi−1).
There are many ways to combine A and Hi−1 to obtain Hi; we provide following
simple example:
Hi = σ(AHi−1Wi)
In the above function, σ is some activation function that operates on the product
AHi−1Wi. It is commonly a ReLU function. A is the adjacency matrix; Hi−1 is the
feature matrix from the previous layer; and Wi is the weight matrix of the current graph-
convolutional layer. A is (N × N), where N is the number of nodes in the graph; Hi−1
is (N × Fi−1), where Fi−1 is the number of features from the previous layer; and Wi is
(Fi−1×Fi), where Fi is the number of features of the current layer. Thus, when multiplied
in series, the output matrix Hi is (N × Fi), which is a feature matrix with an arbitrary
number of features.
Multiplying the adjacency matrix with the feature information serves as a way to
blindly convolve/combine the two together. Further weighting different values of the re-
sulting matrix with the network’s own weight matrix allows the network to learn which
features-edge relationships are most relevant to accurately making predictions. In prac-
tice, f(A,Hi−1) is typically more complex than our example, but this is sufficient to have
a general understanding of the process.
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After passing in the initial feature matrix and adjacency graph into the first layer, suc-
cessively passing the output (and the adjacency matrix) through more graph-convolutional
layers while downsizing the number of resulting features of each output feature matrix
allows a GCN to obtain a wholistic view of the provided information’s trends, from more
specific in earlier layers to more general in later layers. After obtaining the output of the
final graph-convolutional layer, we have a compacted, generalized feature matrix of the
original input that hopefully contains as much relevant information as possible. We can
pass this feature matrix as input into standard DNN layers to make predictions about the
graph.
As a general example of a GCN problem, let us suppose we have an incomplete graph
that contains all nodes but not all edges. We then want to predict the missing edges into the
graph. In practice, providing the GCN with the entire adjacency matrix would not be very
helpful, especially if the graph were very large. It would be very difficult for the network
to make extrapolations from the entire data set. Thus, instead of providing the entire adja-
cency matrix and feature matrix, we can provide subparts of the graph and feature matrix
to the GCN. There are many ways to do so. For example, we could select a random edge
from the graph and provide the two feature vectors of the nodes forming the edge. The
network would then try to learn, from one edge at a time, why two nodes share an edge.
However, this would be very slow. A better approach would be to provide the network
with a subgraph and a subfeature matrix. This subgraph can be constructed by randomly
selecting a few nodes and forming an adjacency matrix between them. The subfeature
matrix would then simply be the matrix consisting of each of the selected nodes’ feature
vector. This allows the dataset to be small enough for the network to learn significant
information while not providing so little of the graph that it can not see general trends.
Additionally, this combats overfitting, as showing the entire graph to the network repeat-
edly would bias the network into just “memorizing” the whole graph. Thus, it would be
16
less likely to predict the missing edges in because it has repeatedly observed that the two
nodes do not share an edge during training.
2.2 Decagon
Of particular interest to this research, Decagon is a GCN created to train on a real-
world Polypharmacy data set [8]. Decagon is designed with the goal of predicting the
safety of drug combinations in Polypharmacy. Decagon’s data set consists of several
databases of drug and protein information aggregated into a massive graph problem. The
data includes many cross-interactions of these drugs and proteins. For example, if two pro-
teins found in the human body are known to interact with each other, then in Decagon’s
graph, the proteins share an edge. Likewise, if a drug is known to interact with a pro-
tein, they share an edge. These edges are undirected and are simple; there is only one
type of edge that can exist between protein-protein and drug-protein pairs which indicates
that the two interact. Similarly, if two drugs are known to have an interaction, called a
side-effect, then an edge exists between the two drugs. In contrast, however, this edge
contains information about the specific side-effect (and is, thus, not simple). For example,
if two drugs’ interaction results in gastrointestinal bleeding, then the edge shared between
them is a gastrointestinal bleeding edge. If two drugs’ interactions result in multiple side-
effects, then they share multiple edges. The end result is a massive, complex graph with
two node types (drugs and proteins) and many edge types (protein-protein edges, drug-
protein edges, and a large set of possible drug-drug side-effect edges). The following is
Decagon’s visualization of their graph:
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Figure 2.1: Decagon’s Visualization of its Graph.
Decagon also has feature information about each of the proteins and drugs which are
based on observed, general properties of the drug-protein data set. This is certainly a very
complicated Polypharmacy problem, which is further complicated by the uncertainty of its
data being observed and not guaranteed to be correct. Additionally, some of the selected
features may not be relevant to determining interactions.
Decagon tests its network by removing some edges from the graph and attempting to
repredict them back in, similar to the previous example of a GCN problem. Despite the
complexity and uncertainty of the data, Decagon appears to be fairly successful. However,
there is much room for improvement. In particular, removing complexity from the problem
and then experimenting on the resulting subproblem may allow for a better understanding
of the problem as a whole.
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3. GCN MODEL
To remove complexity from Decagon’s problem, we propose the following simpler but
nontrivial, theoretical Polypharmacy graph for which we can design a GCN model and
learn to make predictions on:
• Generate a drug graph where an edge between two drugs indicates that they cause a
side-effect.
• There is only one node type and one edge type. Thus, the graph is simple and
undirected.
The following is an example drug graph:
Figure 3.1: An example drug graph.
If the graph were entirely randomly generated, there would be nothing to learn. There-
fore, we propose the following method of generating the drug graph:
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• Generate N random (x, y) pairs, where N is the number of drugs in the graph and
0 ≤ x, y ≤ 1. Each (x, y) pair is a drug’s hidden embedding that is used to determine
which drugs it shares an edge with.
• Calculate the Euclidean distance between each drug’s hidden embedding. If the
distance is below an arbitrary threshold, an edge exists between the drug pair.
– d =
√
(x1 − x2)2 + (y1 − y2)2. Check d ≤ threshold.
This process can be visualized as picking random points in a 2-dimensional plane.
Then, if the distance between the two points is sufficiently small, they share an edge. The
following could be the 2D visualization of the hidden embeddings of our example graph:
Figure 3.2: Hidden Embeddings of our Example Graph.
While the hidden embeddings are randomly selected, there is a logical and consistent
reason for an edge existing between two nodes. Therefore, it is possible to make accurate
predictions on the graph.
The hidden embedding of each drug can be thought of as the drug’s true feature values.
There is only a small number of features, and the relationship between drugs is fairly
simple. Many ML problems often appear more complex than they truly are. We may
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believe a problem is dependent on many factors when, in reality, many of these factors are
either irrelevant or completely dependent on other factors. For example, we may observe
that a drug affects blood pressure and also affects blood sugar levels; and we may think
these properties are unrelated. However, the drug may affect blood pressure specifically by
affecting blood sugar levels. In reality, we should only care about whether the drug affects
blood sugar levels; but uncertainty prevents us from observing this. Often, the problem
is actually dependent on a small number of factors, modeled in our problem by the small
number of true features of a drug. To simulate the uncertainty of observing a problem’s
complexity, we artificially stretch the number of features to a much higher dimension.
This stretched set of features represent the “observable” features of the problem. Thus,
the GCN network never sees the hidden embeddings of the drugs; instead, it only sees the
“observable” features.
To stretch the hidden embeddings of each drug to a higher dimensional space, we can
simply generate a random (2 × F ) matrix, where F is the desired dimensionality. Then,
we can take the dot product of a drug’s hidden embedding and the stretch matrix to get a
(1 × F ) matrix. This way, instead of seeing the two true features of a drug, the network
sees what appears to be a much more complicated problem. The following is an example:
If a drug has the following hidden embedding:
(
.43 .75
)
and our stretch matrix is
.42 .24 .83 .74
.19 .51 .68 .06
 ,
then their dot product will yield
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(
.32 .49 .87 .36
)
.
This matrix is (1 × F ). We can do this for the rest of the drug embeddings. It is
important that we use the same stretch matrix for each drug embedding; otherwise, the
problem would be random and unsolvable. Taking the dot product of each hidden drug
embedding and the same stretch matrix creates a (N ×F ) feature matrix. Thus, we have a
complete adjacency matrix and corresponding feature matrix and can now discuss training.
Similarly to Decagon, we will train on subgraphs of the network with the goal of
predicting in edges. Unlike Decagon, however, we do not remove edges from the graph
and attempt to repredict them back in. Instead, we do the following:
• Select K nodes randomly from the graph. Create the subgraph of the K nodes. This
matrix is (K ×K).
• Create the corresponding subfeature matrix. This matrix is (K × F ).
• Select a random pair of nodes. These are the two nodes we want to predict whether
an edge exists between. It is important that at most one of these nodes is in our
subgraph; otherwise, the problem would be trivial.
Over time, we hope that the network will learn that the problem is less complicated than
it appears and begins to make accurate predictions despite not having the true embeddings,
much like a real problem.
With the construction of our theoretical data set and discussion of the network’s train-
ing method complete, we now discuss the model of our GCN network, which can be found
at https://github.com/BenjaminDantonio/ResearchGCN.
The GCN takes the following as input:
• A (K ×K) subgraph of randomly selected nodes.
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• A (K × F ) subfeature matrix of the randomly selected nodes.
• A pair of nodes to predict whether an edge exists between them, where at most one
node is in the subgraph.
And outputs:
• A single value: 0 or 1, where a 1 indicates that the GCN believes the two nodes have
an edge and, thus, believes that the two drugs would cause a side-effect.
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The following is the GCN’s model:
Figure 3.3: Model of our GCN.
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Input-Data is the subfeature matrix, and Input-Edge is the subgraph of the adja-
cency matrix. These are both passed into the first graph-convolutional layer, graph_conv_1.
The output of graph_conv_1 is a convolved feature matrix. This matrix is (K × F1),
where F1 is the arbitrary number of output features for graph_conv_1. This continues
for the next two graph-convolutional layers, generating a (K × F2) matrix and finally a
(K × F3) matrix. F > F1 > F2 > F3, so at each step, we convolve the feature ma-
trix into a smaller size. The final feature matrix of the third graph-convolutional layer is
sufficiently dense to make a prediction with. We pass this final feature matrix into a flat-
ten layer, which simply “flattens” the matrix into one row. That is, our (K × F3) matrix
becomes (1×KF3), where each row is concatenated to the first row.
Thereafter, we take the feature vectors of the two drugs we are predicting an edge
between (Pairs-Data-1 and Pairs-Data-2) and concatenate them to this flat, con-
volved matrix using concatenate_1 to get a (1 × (KF3 + 2F )) matrix, which is just
a vector of length (KF3 + 2F ). This could serve as an “input layer” for a normal DNN.
We use it the same way here, passing the vector as input to what is essentially a DNN with
three layers.
We pass the input layer through three dense layers, which are the standard layer of
a DNN consisting of an arbitrary number of neurons, with each successive dense layer
having fewer neurons. The final layer, dense_3 has one neuron with a sigmoid activation
function. Thus, the output of this layer is either a 0 or a 1. This represents the network’s
prediction for whether an edge exists between the two provided nodes. As with any DNN,
the network adjusts its activation values based on feedback on its prediction.
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4. EXPERIMENTAL RESULTS
We trained the network and evaluated its performance on the following metrics:
• Accuracy: The percentage of correct predictions over total predictions. If the net-
work predicted correctly 9 out of 10 times, it would have a 90% accuracy.
• Loss: A measure of how well our network is modeling the dataset. A smaller loss
value indicates less uncertainty and, thus, indicates that our network is learning the
data. We use binary crossentropy as our loss function, as it is most appropriate for
making binary classifications. Binary Crossentropy is calculated as follows:
BCEp = − 1
N
N∑
i=1
yi ∗ log(p(yi)) + (1− yi) ∗ log(1− p(yi))
This formula is not as complicated as it appears. N is the number of predictions
being made. Thus, we are taking a summation on our predictions. The summation
can be broken into two halves along the +. The second half is the compliment of the
first. yi is the actual answer that the prediction should be. Thus, if two drugs cause
a side-effect, yi = 1, else 0. p(yi) is the prediction’s probability that two drugs will
cause a side-‘effect, a value between 0 and 1. Thus, the first half of the summation
will, for every time a prediction’s answer is 1, add the log of p(yi) to the total; else
it will add 0. The second half of the summation will, for every time a prediction’s
answer is 0, add the log of the compliment of p(yi), 1 − p(yi), to the total; else, it
will add 0. This way, we calculate the distance between the actual answer and the
network’s prediction for every prediction, measuring the amount of uncertainty in
the network’s model of the dataset.
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• F1 Score: A measure of accuracy useful in binary classification where the ratio
of 1’s to 0’s is not even. F1 Score measures how well the network is learning–
not predicting. F1 Score becomes important when the answer is 1, for example,
90% of the time. If the network simply outputs 1 every time, it will have a 90%
accuracy. This is deceptive because the network needs no understanding of the data
set to achieve 90% accuracy. The F1 Score is a value between 0 and 1, where 1
is the best possible F1 Score, and measures the Precision (p) and Recall (r) of a
network’s predictions to determine if the network is blindly guessing or actually
making predictions. F1 Score is calculated as follows:
F1 = 2
pr
p+ r
Precision is a measure of true positives (tp) and false positives (fp) and can be cal-
culated as follows:
p =
tp
tp+ fp
So Precision is true positives over all predicted positives. Thus, if a network outputs
1 every time, it will accrue a lot of true positives but also a lot of false positives.
Overall, this will lower the network’s Precision.
Recall is a measure of true positives (tp) and false negatives (fn) and can be calcu-
lated as follows:
r =
tp
tp+ fn
So Recall is true positives over all actual positives. Thus, if a network outputs 1
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every time, it will accrue a lot of true positives and no false negatives. Overall, this
will increase the network’s Recall.
Putting Precision and Recall together, if a network outputs 1 every time and earns a
90% accuracy, its F1 score will still be low because its Precision and Recall will be
balanced/harmonized together, indicating that the network is not actually learning.
4.1 Performance Evaluation
These metrics were gathered for both training and testing phases, so we have Training
Accuracy, Testing Accuracy, etc., totaling six metrics. The six metrics were gathered for
three tests with differing graph edge densities: 10%, 25%, and 50%. Graph edge density
is the measure of the actual number of edges in the graph to the potential number of edges.
For example, in a graph with ten drugs, the number of potential edges is (102 − 10)/2.
Because we have ten drugs, the graph can be represented as a (10×10) adjacency matrix–
100 possible slots. Removing the option for self-edges removes 10 slots. The graph is
undirected, so if (x, y) in the matrix = 1, (y, x) in the matrix also = 1, which halves the
total number of potential edges. Thus, we arrive at the total number of potential edges
being (102 − 10)/2 = 45 for ten drugs. If 5 of those edges randomly end up being a 1
due to the arbitrary value of the distance threshold, then the graph has an edge density of
5/45 = 11%. Additionally, for each of the three densities, we tested the following two
factors independently and then together: doubling the number of drugs in the network and
doubling the number of observable features for each drug. Thus, we performed three edge
density tests for the following four trials: a graph with base values (which will be speci-
fied), a graph with twice the number of drugs as base, a graph with twice the number of
observable features as base, and a graph with both twice the number of drugs and twice the
number of observable features as base. With these tests, we demonstrate the effectiveness
of our GCN to learn our Polypharmacy problem across different edge densities even as the
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problem increases in difficulty.
The following are the base values of the graph which the GCN trained on:
• Number of Drugs: 2000.
• Number of Latent Features: 2.
• Number of Observable Features: 32.
• Number of Subgraphs: 1500. (Not guaranteed to be unique.)
• Number of Drugs in a Subgraph: 10.
• Number of Drug Pairs for Each Subgraph: 8. (Guaranteed to be unique per Sub-
graph. At most one drug appears in the Subgraph.)
The following are the GCN’s training parameters:
• Validation Split: 10%. (The percentage of the Subgraph/Drug Pairs reserved for
testing.)
• Number of Epochs: 20.
• Batch Size: 16.
4.2 Trial 1
This trial contains the results of the three edge densities on the base values of the graph.
Each metric is measured as its average over all epochs.
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Results (Average)
Metric\Edge Density 10% 25% 50%
Training Accuracy 0.972 0.965 0.959
Training Loss 0.066 0.081 0.095
Training F1 Score 0.699 0.902 0.955
Test Accuracy 0.977 0.961 0.964
Test Loss 0.0521 0.093 0.083
Test F1 Score 0.742 0.909 0.958
In each edge density test, the network’s performance far exceeded that of being random
guesses. Each test achieved over 95% average accuracy for both training and testing.
The loss in all cases was very small, as expected with high accuracy. It should be noted
that despite a high accuracy on the 10% edge density test, the network’s F1 score took a
moderate downturn. This is likely something that can be corrected with proper parameter
tuning. However, a lower edge density is generally a harder problem to achieve a high
F1 score on, so the result is not unexpected. Aside from the 10% test, the F1 score was
particularly strong. Overall, the network seems to be fitting very well, as the training and
testing results are similar and strong.
4.3 Trial 2
This trial contains the results of the three edge densities on the base values of the graph,
except with the number of drugs doubled from 2000 to 4000. Each metric is measured as
its average over all epochs.
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Results (Average)
Metric\Edge Density 10% 25% 50%
Training Accuracy 0.972 0.960 0.958
Training Loss 0.068 0.090 0.096
Training F1 Score 0.656 0.894 0.954
Test Accuracy 0.972 0.962 0.971
Test Loss 0.069 0.083 0.071
Test F1 Score 0.696 0.904 0.968
This trial’s results are similar to Trial 1’s. The network’s average accuracy never drops
below 95%. Similarly, the loss was very small. While the F1 Score of the 10% test was
lower than Trial 1’s, the other tests achieved a similar F1 Score. Even with the increased
number of drugs, the network fits strongly. Overall, this indicates that the GCN is capable
of scaling well with the size of the graph, as doubling the number of drugs in the graph
had little effect on the network’s performance.
4.4 Trial 3
This trial contains the results of the three edge densities on the base values of the graph,
except with the number of observable features of each drug doubled from 32 to 64. Each
metric is measured as its average over all epochs.
31
Results (Average)
Metric\Edge Density 10% 25% 50%
Training Accuracy 0.970 0.962 0.957
Training Loss 0.070 0.087 0.096
Training F1 Score 0.675 0.896 0.955
Test Accuracy 0.979 0.971 0.954
Test Loss 0.051 0.068 0.102
Test F1 Score 0.717 0.919 0.951
This trial’s results hold true to the previous two trials’. From this, we can conclude that
increasing the apparent complexity of a drug’s features does not hinder the network from
performing strongly. That is, it can still understand the underlying, less complex nature of
a drug’s features despite the presented complexity.
4.5 Trial 4
This trial contains the results of the three edge densities on the base values of the graph,
except with the number of drugs doubled from 2000 to 4000 and the number of observable
features of each drug doubled from 32 to 64. Thus, Trial 4 is a combination of Trial 2
and 3. This trial questions whether both of these factors scaling together might cause an
interaction that negatively affects the network’s performance. Each metric is measured as
its average over all epochs.
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Results (Average)
Metric\Edge Density 10% 25% 50%
Training Accuracy 0.971 0.961 0.957
Training Loss 0.067 0.087 0.098
Training F1 Score 0.666 0.897 0.953
Test Accuracy 0.970 0.970 0.957
Test Loss 0.067 0.073 0.101
Test F1 Score 0.637 0.892 0.956
For the 25% and 50% edge density tests, the simultaneous increase in the number
of observable feature values and number of drugs in the graph appeared to have little to
no effect. However, in the 10% test, the Test F1 Score dropped a moderate amount. This
likely indicates that the effect of these two features’ interaction becomes more pronounced
when the network has fewer positive examples to learn from. Whether this can be resolved
with proper tuning remains to be investigated. Despite the lower F1 Score, however, the
network still performed as strongly as previous trials in the 10% test.
4.6 Experimental Results Summary
Overall, the GCN performed around the same in terms of accuracy for each test in
each trial. The GCN performed slightly worse in terms of loss across all trials as the edge
density approached 50%. However, this is likely not significant. The GCN performed
better in terms of F1 Score as the edge density approached 50%. This is notable. It
indicates that the network has more difficulty with lower density networks, which is not
wholly surprising. Perhaps tuning the network better could improve its performance on
low density graphs.
It should be noted that the GCN was created to be as generic as possible. It has three
graph convolutional layers and three dense layers to mirror each other, and their parame-
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ters’ values are simply based on powers of two to stay generic. A great amount of tuning
is possible, which would likely increase the effectiveness of the network for any of these
trials or edge densities. Despite this, the network still performed strongly.
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5. CONCLUSIONS
In this thesis, we have shown that the field of Polypharmacy stands to benefit greatly
from ML. We have presented the foundations for ML, DL, and DNNs. We have surveyed
current methods of applying ML to Polypharmacy problems, namely GCNs. We have
rigorously defined a theoretical Polypharmacy problem and created a GCN that strongly
models the problem. This base model demonstrates the potential for GCNs to learn on a
Polypharmacy problem.
There is still much work to be done, however. Further steps include the following:
• Tuning the network to better model the theoretical problem.
• Generalizing the theoretical model to fit other models.
• Applying the network to a real-world Polypharmacy problem.
Tuning the network would certainly help the network’s overall performance. In par-
ticular, tuning the network to have a higher F1 Score for low density networks is the
most important improvement to be made currently. This is because many Polypharmacy
problems have low density networks, as drugs do not commonly interact with many other
drugs.
Generalizing the theoretical model to be applicable to other models would be a great
boon in understanding GCN’s potential in Polypharmacy. For example, instead of using a
simple, undirected drug graph, the network could learn on a nonsimple, undirected graph
where drugs can share multiple edges. Each edge could represent a certain side-effect.
Thus, for a given drug pair, the network would predict whether the two drugs’ interaction
causes each side-effect. Another option is to instead attempt to model a graph with the
addition of protein nodes which have their own interactions with drugs and other proteins.
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This would provide more information to the network, as two drugs that interact with the
same protein may be more likely to cause a side-effect together.
Once the model has been generalized enough, it would be interesting to see how it
performs on a real Polypharmacy problem. For example, given a historical database of
drug interactions similar to our model, the network could learn to predict whether two
drugs that have not been used together will cause a side-effect.
We look forward to future research expanding on the application of GCNs to Polyphar-
macy problems.
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